Early trial tests new weapon against advanced cancers
NCT ID NCT06049212
Summary
This early-stage study is testing the safety of a new cancer drug called sacituzumab tirumotecan in Japanese patients. The drug is being given alone and in combination with an existing immunotherapy (pembrolizumab) to people with advanced solid tumors or a specific type of advanced lung cancer. The main goal is to find safe doses and understand how the body processes the drug, not to cure the disease at this stage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center ( Site 0006)
Nagoya, Aichi-ken, 464-8681, Japan
-
Kanagawa Cancer Center ( Site 0004)
Yokohama, Kanagawa, 241-8515, Japan
-
Kansai Medical University Hospital ( Site 0007)
Hirakata, Osaka, 573-1191, Japan
-
National Cancer Center Hospital ( Site 0001)
Chuo-ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East ( Site 0002)
Kashiwa, Chiba, 277-8577, Japan
-
National Hospital Organization Shikoku Cancer Center ( Site 0008)
Matsuyama, Ehime, 791-0280, Japan
-
Shizuoka Cancer Center ( Site 0005)
Nagaizumi-cho,Sunto-gun, Shizuoka, 411-8777, Japan
Conditions
Explore the condition pages connected to this study.